TB-500 (Thymosin Beta-4 Fragment): The Wound Healing Peptide Explained
Regulatory Update (April 2026): TB-500 is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 23, 2026. The committee will evaluate TB-500 for wound healing and consider it for the Section 503A Bulk Drug Substances List. Read our full coverage: FDA to Review 7 Peptides for Compounding List in July 2026.
TB-500 is a synthetic peptide built from a short fragment of a naturally occurring protein called thymosin beta-4. Researchers and clinicians have studied it for wound healing, soft tissue repair, and inflammation. The FDA is now reviewing TB-500 for possible inclusion on the 503A Bulk Drug Substances List, which would open a clearer legal pathway for compounding pharmacies to work with it. This guide explains what TB-500 is, how it works, and where the science currently stands.
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
| Topic | Detail |
|---|---|
| What it is | Synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino-acid protein |
| Active sequence | Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ), often written as the active region of Tβ4 |
| Primary research focus | Wound healing, tendon and ligament repair, cardiac tissue recovery |
| Mechanism | Binds G-actin, promotes cell migration, angiogenesis, and anti-inflammatory signaling |
| Administration | Subcutaneous or intramuscular injection |
| FDA status | Not FDA-approved; under PCAC review July 23, 2026 for 503A Bulks List inclusion |
| WADA status | Prohibited in competitive sport under the S2 category |
What Is TB-500?
Thymosin beta-4 is a small protein found in nearly every cell of the human body. It plays a central role in how cells move, how wounds close, and how tissue regenerates after damage. TB-500 is the synthetic research peptide based on the active region of that protein. The FDA notice describes TB-500 and its acetate form together as a single bulk drug substance under review. Clinicians and researchers who work with peptides typically use the terms TB-500 and thymosin beta-4 fragment interchangeably, though the two are not chemically identical.
How TB-500 Works
The mechanism centers on a protein called G-actin. TB-500 binds G-actin and helps move it where the body needs it for cellular movement and tissue repair. That single interaction has downstream effects across several healing pathways. It supports the migration of stem cells and progenitor cells to sites of injury. It promotes the formation of new blood vessels, a process called angiogenesis. It dampens inflammatory signaling during the repair phase of healing. Research published in Annals of the New York Academy of Sciences describes these mechanisms in detail.
The Research on Wound Healing
Wound healing is the specific use the FDA is reviewing. Most of the published evidence on TB-500 comes from animal models and cell culture experiments. Studies have shown accelerated closure of skin wounds in rodents, improved recovery after corneal injury, and faster repair of cardiac tissue after simulated injury. A smaller body of early human research has explored thymosin beta-4 in clinical settings including diabetic foot ulcers and dry eye disease. Results have been promising enough to justify continued investigation, though larger randomized trials are still limited.
TB-500 in Musculoskeletal Recovery
Outside the official wound healing indication, TB-500 has drawn attention in sports medicine and orthopedic settings. Clinicians using it off-label describe faster recovery from tendon injuries, muscle strains, and chronic soft tissue problems that have not responded to standard care. Much of the enthusiasm traces back to animal studies showing improved tendon and ligament healing after TB-500 administration. Clinics offering peptide therapy often pair TB-500 with BPC-157 for injury recovery protocols.
Find verified providers in our BPC-157 & recovery peptide clinic directory.
Administration and Dosing
TB-500 is almost always administered by injection. Most protocols use subcutaneous delivery with a small insulin-style needle. Some practitioners prefer intramuscular injection for localized effects near an injured site. Dosing protocols vary. Loading phases with higher weekly doses are often followed by maintenance dosing. Every clinical decision should come from a licensed physician who has reviewed the patient’s full health history and current medications. There is no oral form that has been shown to be effective because the peptide breaks down in the digestive tract.
Safety and Side Effects
Published safety data on TB-500 in humans is limited. Reported side effects include temporary fatigue, mild injection site reactions, and occasional headaches. The peptide affects cell proliferation and angiogenesis, which raises theoretical concerns about its use in patients with active cancer. Most clinicians screen for malignancy before starting therapy and avoid TB-500 in patients with untreated cancers. Because the long-term safety profile is not fully characterized, ongoing clinical oversight during therapy is standard.
Regulatory Status and Athletic Use
TB-500 is not approved by the FDA for any indication. Until the outcome of the July 2026 PCAC review is known, it sits in a gray zone. The World Anti-Doping Agency prohibits TB-500 in competitive sport under the S2 category of peptide hormones, growth factors, and related substances. Athletes who compete under WADA jurisdiction should treat TB-500 as a banned substance. For non-athletes considering TB-500 therapy, legal access depends on the outcome of the FDA review and the policies of individual compounding pharmacies.
Cost and Access
TB-500 is not covered by insurance. Cash-pay costs vary widely across compounding pharmacies and peptide clinics. A typical monthly supply at common therapeutic doses usually ranges from $200 to $500. Loading phases with higher weekly doses cost more. Clinic consultation and lab work add additional cost. Patients considering TB-500 therapy should expect to pay out of pocket and should ask their provider exactly which compounding pharmacy is filling the prescription.
What the July 2026 FDA Review Means
The Pharmacy Compounding Advisory Committee meeting on July 23, 2026 will evaluate whether TB-500 should be added to the 503A Bulks List for wound healing. A positive recommendation followed by FDA action would formalize the compounding pathway that many clinics have been using informally. A negative recommendation would push TB-500 further outside the legal compounding framework. Either way, the outcome will shape how patients access the peptide. Patients and clinicians can submit written comments to the FDA docket by July 9, 2026 to have their input reviewed by the committee.
Finding a Peptide Clinic
If you are considering TB-500 therapy, work with a licensed provider who can order baseline labs, review your health history, and monitor your progress. Our peptide therapy directory lists verified clinics across the country that offer peptide protocols under physician supervision. For a broader overview of how peptide therapy works, see our complete guide to peptide treatments.
Related providers:
Related provider: Saving Face Austin
Related provider: InnerTrek Facilitator Training ‘ Portland, Oregon
Related providers:
Related provider: MindPath Sacramento ‘ Sacramento, California
Related providers:
Related providers:
